|Day's Range||77.8000 - 78.2800|
|52 Week Range||64.1800 - 86.7200|
|PE Ratio (TTM)||37.70|
|Dividend & Yield||2.08 (2.70%)|
|1y Target Est||N/A|
AstraZeneca plc (AZN) announced top-line results from the EXSCEL study evaluating the cardiovascular (CV) safety profile of its type II diabetes drug Bydureon.
Novo Nordisk stock popped Tuesday after AstraZeneca said its Type 2 diabetes drug didn't reduce the risk of cardiovascular events in a trial.
Certain pharma stocks have significant upside potential.